230 results
Page 6 of 12
S-8
ysw34gg7vd
4 Feb 21
Registration of securities for employees
5:27pm
S-8
EX-23.1
25cklwyq4nvmofmrxz
4 Feb 21
Registration of securities for employees
5:27pm
424B3
akfnmfxy3jed6s8b
26 Jan 21
Prospectus supplement
5:02pm
8-K
EX-4.1
syr9gi8tq1vmggvzz
26 Jan 21
Entry into a Material Definitive Agreement
9:16am
424B5
qxshi7wjm3ca8b
22 Jan 21
Prospectus supplement for primary offering
5:24pm
8-K
EX-3.1
bdcrn caixobywx
13 Jan 21
KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
12:00am
8-K
EX-4.4
rbzbwx
13 Jan 21
KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
12:00am
8-K
EX-4.3
htv533 rcvqmmj
13 Jan 21
KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
12:00am
424B4
oba1g81w
8 Jan 21
Prospectus supplement with pricing info
9:38pm
POS EX
EX-4.10
f91fe
8 Jan 21
Additional exhibits for listing
12:00am
POS EX
EX-1.1
a8gcxn2bmv0byzirfv3i
8 Jan 21
Additional exhibits for listing
12:00am
POS EX
EX-4.11
njda54s3oem8
8 Jan 21
Additional exhibits for listing
12:00am
S-1MEF
4ufso b2vql
7 Jan 21
Registration of additional securities for an S-1
6:11pm
S-1MEF
EX-23.1
b9m9b bfd0
7 Jan 21
Registration of additional securities for an S-1
6:11pm
8-K
EX-99.1
3suzqg72
5 Jan 21
Sven Guenther, Ph.D., our executive vice president, research and development; and Summary Compensation Table
9:10am